CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 197 enrolled
Drug / intervention
moxifloxacindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02114684
NCT02114684Phase 2Completed
CompareCT.gov

An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB

Centre for the AIDS Programme of Research in South Africa·interventional·Posted Apr 15, 2014·Updated Aug 5, 2019

In Brief

A Phase 2 clinical trial evaluating moxifloxacin for Recurrent Tuberculosis. Completed, enrolled 197 participants across 1 site.

Detailed Summary

This is an open label randomized controlled clinical trial comparing two regimens for treatment of smear-positive pulmonary TB, among patients previously treated for TB. The primary objective is to determine if a moxifloxacin-containing regimen, substituting moxifloxacin for ethambutol, of 24 weeks duration is superior to a control regimen of 24 weeks duration in improving treatment outcomes in patients with recurrent TB and shortens the duration of TB treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Tuberculosis
CountriesSouth Africa
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 15, 2014
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2017
Study CompletionJul 17, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.2 years ago

Interventions

moxifloxacindrug

\[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]